Shows
IP Cafe by InfoPathwaysEpisode 108: The Many Lives of Dr. HJoin in as Desmond and Alec dive deep with Dr. H as they talk about everything from how he got to where he is today, all the way to his vast musical skills!You will not want to miss this this and learning about the new things he is working on with Capital Biologics! Find out more by visiting their website!https://www.biofactura.com/capitol-biologics/https://www.linkedin.com/company/society-of-physician-entrepreneurs2025-07-1651 minIP Cafe by InfoPathwaysEpisode 107: That's So RavennaThis week Desmond and Alec sit and talk with Ravenna about everything marketing and InfoPathways. Listen in as we cover some of the things that make IP unique and our approach to marketing.2025-03-111h 10IP Cafe by InfoPathwaysEpisode 106: That's Valid! with Stephanie BrandfordDive into the world of Validation with Desmond and Alec as they meet with Stephanie Brandford from Brayearst Validation Consulting.
Website: brayearst.com
Schedule time: meet.brayearst.com
Youtube: youtube.brayearst.com
LinkedIn: linkedin.brayearst.com
More info: flyer.brayearst.com2025-01-281h 12
IP Cafe by InfoPathwaysEpisode 105: Coffee with KellyTake a listen as Desmond and Alec talk with Kelly Schulz, CEO of the Maryland Tech Council, about everything from education, energy and how technology is the backbone of so many industries today.2024-10-291h 16
IP Cafe by InfoPathwaysEpisode 104: Buzzin' with Chris FrewListen in as Desmond and Alec dive in with Chris Frew to discuss everything from Biobuzz to the community that it serves!
2024-10-151h 06
IP Cafe by InfoPathwaysEpisode 103: Lights, Camera, Action!Tune in as we talk with Richard Turner, Executive Director from the Community Media Center, as we see how technology has changed the broadcasting industry. From fiber internet, modern streaming platforms as well as local sports play calling!2024-10-091h 05
IP Cafe by InfoPathwaysEpisode 102: Me, Myself and A.I.Listen in as hosts Desmond Grimes and Alec Schapiro dig into the world of A.I. and how it can be used in more ways than just to create random images!
We chat with Jake Butt from GxP Solutions to learn more!2024-08-221h 20IP Cafe by InfoPathwaysEpisode 101: The BeginningFor our first podcast where else to start but "The Beginning" of InfoPathways. Hosts Desmond Grimes and Alec Schapiro sit down with owners Thom and Theresa Bethune.
Join in as we discuss the humble beginnings of InfoPathways and see what the future may hold for this "ITSP Company" (information technology solutions provider) as Desmond so coins in today's episode.
2024-07-101h 11
Breaking Biotech112 - Biotech Updates - $BTAI $TGTX $CRIS $CKPT $KPTI $SRRAIn this episode, I take a look at 6 different biotechs and talk about recent updates in each one. Here is the breakdown:
BTAI - 1:00
TGTX - 5:25
CRIS - 18:00
CKPT - 22:39
KPTI/SRRA - 31:07
Thanks to InfoPathways for being a sponsor of the show! Check them out for all your biotech IT needs at infopathways.com or call 410-751-9929.
Help out the show (or join the discord) by becoming a patron at: https://www.patreon.com/breakingbiotech Follow me on twitter @matthewlepoire
Send me an email matthewlepoire@gmail.com www.breakingbiotech.com #breakingbiotech
...2022-04-2143 minBreaking Biotech111 - Achieve Life Sciences Phase 3 Readout Imminent! Interview with CEO John BencichAchieve Life Sciences is developing Cytisinicline for the treatment of smoking cessation. The drug has been available in Eastern Europe for years, but Achieve has taken the lead to bring this drug to market in developed countries. The safety profile is significantly better than both Chantix and Zyban and they are about to release data from the first of two Phase 3 clinical trials (ORCA-2 and ORCA-3). Given that there are 31M Americans who smoke and that e-cigarette usage is on the rise, there will be a large market of people who can benefit from Cytisinicline.
Thanks to...2022-04-0128 minBreaking Biotech110 - Kodiac Sciences FALLS on Negative Wet AMD Readout! Buying Opportunity or Falling Knife??Kodiac Sciences is developing KSI-301 for a number of proliferative endothelial retinal disorders. Their recent P3 wet AMD data readout failed to show non-inferiority to Q8W dosed Eylea, a major upset for the company. However, KOD has a number of other upcoming P3 trial readouts that will be massive movers for the stock. In this episode, I go over the P3 data and talk about whether or not this is a buying opportunity. I also talk about Karyopharm and their recent regulatory update about the SIENDO data.
Thanks to InfoPathways for being a sponsor of the show! Check...2022-03-0533 minBreaking Biotech109 - Karyopharm Guides INCREASED Sales Growth in 2022 and Reports Positive SIENDO ResultsKaryopharm is an oncology company that is commercializing XPOVIO (Selinexor) in Multiple Myeloma and DLBCL. Selinexor blocks nuclear export thereby hindering the ability of cancer cells to block tumor suppressor protein activity. In this episode, I break down the bear and bull narratives of Karyopharm and discuss how the company has transitioned since entry of the new CEO Richard Paulson.
Thanks to InfoPathways for being a sponsor of the show! Check them out for all your biotech IT needs at infopathways.com or call 410-751-9929.
Help out the show (or join the discord) by...2022-02-2233 minBreaking Biotech108 - NASH Companies to Watch in 2022! Madrigal Pharma Announces Positive Data in NAFLDThe NASH space has seen some setbacks in the last couple years, but a few players continue to make nice progress on their clinical trials. Madrigal Pharma announced positive topline data in their MAESTRO-NAFLD trial, which is an encouraging sign for their upcoming readout in NASH in Q3-2022. I discuss other players in the space including: ETNB, AKRO, VKTX, ICPT, IVA and NVO.
Checkpoint Therapeutics announces positive topline data from their trial of Cosibelimab in metastatic cutaneous squamous cell carcinoma. I talk to about what we can look forward to in 2022 for this company as well. 2022-02-0837 minBreaking Biotech107 - CymaBay Sets to Massively Improve Outcomes in PBC Patients | Interview with CEO Sujal ShahCymaBay Therapeutics is developing Seladelpar for the treatment of Primary Biliary Cholangitis (PBC). PBC currently affects around 130K patients in the USA and current available treatments do not address patient needs sufficiently. Seladelpar is an oral, selective PPARĪ“ agonist that has been shown to regulate critical metabolic and liver disease pathways. CymaBay is currently enrolling for a registrational Phase 3 program in PBC with topline data expected in 2023. Data from prior trials show that Seladelpar significantly improves ALP as well as ALT/AST. On top of that, patients taking Seladelpar have reductions in pruritus and improvements in other important biomarkers...2022-01-2935 minBreaking Biotech106 - Bright Spot Among CRISPR in Caribou Biosci. 2022 Biotech Trends to Watch!CRISPR is an exciting space, with a number of companies finally sharing early clinical data in 2021. NTLA benefitted the most from this by doubling in valuation after data release, while the other CRISPR companies continue to trend lower in the XBI bear market. Caribou Biosciences is one of the smaller EV CRISPR companies with their first clinical readout coming up in 2022. In this episode, I go through a short primer on all the CRISPR companies and discuss why I think Caribou will have a great year.
2022 is on track for another exciting year in biotech - despite...2022-01-0942 min